

EXPRESS MAIL CERTIFICATE

Date 3/7/01 Label No. EL706723006 t18

5 I hereby certify that, on the date indicated above I deposited  
this paper or fee with the U.S. Postal Service & that it was  
addressed for delivery to the Assistant Commissioner of  
Patents & Trademarks, Washington, DC 20231 by  
"Express Mail Post Office to Addressee" service.



10 A. DiLullo A. DiLullo  
Name (Print) Signature

07278  
PATENT TRADEMARK OFFICE

15

2427/1G685US1

20 **HIGHLY EFFICIENT GENE TRANSFER INTO HUMAN REPOPULATING  
STEM CELLS BY *RD114* PSEUDOTYPED RETROVIRAL VECTOR PARTICLES**

This application claims priority under 35 U.S.C. §119(e) of provisional  
patent application Serial NO. 60/187,534, filed March 7, 2000, which is incorporated  
herein by reference in its entirety.

25 The research leading to the present invention was supported in part by  
National Institutes of Health Grant P01 HL 53749. The United States Government may  
have certain rights in the invention.

**FIELD OF THE INVENTION**

30 The present invention relates to a method for efficiently introducing  
exogenous genes into stem cells, particularly human repopulating stem cells, using  
retroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114)  
envelope protein. The gene transfer method of the present invention is important for  
somatic cell gene therapy, for studying the differentiation of various cell lineages, and for  
35 creating animal models of various human stem cell conditions.

**BACKGROUND OF THE INVENTION**

**Use of Retroviral Vectors for Gene Therapy**

Gene therapy is a novel method under investigation for the treatment of

genetic, metabolic and neurologic diseases, cancer and AIDS. The primary goal of gene therapy is to deliver a specific gene to a pre-determined target cell, and to direct expression of such a gene in a manner which will result in a therapeutic effect.

Compared to more traditional methods of gene transfer, retroviral vectors  
 5 are extraordinarily efficient gene delivery vehicles (for reviews *see* Vile *et al.*, Br. Med. Bull. 1995, 51:12-30; Klimatcheva *et al.*, Front Biosci., 1999, 4:D481-96). The retroviral genome becomes integrated into host chromosomal DNA, ensuring its long-term persistence and stable transmission to all future progeny of the transduced cell and making retroviral vector suitable for permanent genetic modification. Up to 8 kilobases of foreign  
 10 gene sequence can be packaged in a retroviral vector particles, which is more than enough for most gene therapy applications. The ability of retroviral vector particles to cause no detectable harm while entering their target cells represents another therapeutically important property. Indeed, there have been no reported short- or long-term toxicity problems associated with the use of the retroviral vectors in human gene therapy trials,  
 15 now dating back to 1989. In addition, these vectors can be manufactured in large quantities, which allows their standardization and use in pharmaceutical preparations.

In view of the properties described above, it is not surprising that retroviral vectors have been selected as the vectors of choice in about 80% of the clinical gene therapy trials that have been approved to date. The most successful of these clinical  
 20 experiments have used T cell-directed retroviral vector-mediated gene transfer to cure a severe combined immunodeficiency (SCID) caused by adenosine deaminase (ADA) deficiency (genetic disease) in humans (for review *see* Onodera *et al.*, Acta Haematol., 1999, 101:89-96).

Most of the commonly used retroviral vectors are of oncoviral origin.  
 25 These vectors require cell division in order to achieve genome integration and long-term gene expression. Accordingly, lentiviral vectors (*e.g.*, HIV-based), which are retroviruses capable of productively infecting non-dividing cells, have been suggested as an alternative approach to successful gene transfer in quiescent somatic cells (Miller *et al.*, 1990, Mol. Cell Biol., 10:4239-4242; Klimatcheva *et al.*, *supra*).

30 **Retrovirus vectors.** Introduction of genes into host animals is described in U.S. Patent No. 5,399,346; Mann *et al.*, Cell, 1983, 33:153; U.S. Patent Nos. 4,650,764 and 4,980,289; Markowitz *et al.*, J. Virol., 1988, 62:1120; U.S. Patent No. 5,124,263;

- European Publication Nos. EP 453 242 and EP178 220; Bernstein *et al.*, Genet. Eng., 1985, 7:235; McCormick, BioTechnology, 1985, 3:689; PCT Publication No. WO 95/07358; and Kuo *et al.*, Blood, 1993, 82:845. Retroviral vectors can be constructed from different types of retrovirus, such as HIV (human immunodeficiency virus), MoMuLV ("murine Moloney leukemia virus"), MSV ("murine Moloney sarcoma virus"), HaSV ("Harvey sarcoma virus"); SNV ("spleen necrosis virus"); RSV ("Rous sarcoma virus"), and Friend virus. In the last decade, several retroviral vector systems, derived from chicken or murine retroviruses, have been developed for the expression of various genes (for reviews *see* Temin, 1987; Gilboa, 1990; Robbins and Ghivizzani, Pharmacol. Ther., 1998, 80:35-47).
- 5 The majority of existing gene therapy protocols use simple retroviral vectors based on Murine Leukemia Virus (MLV). These vectors are able to infect many different cell types, and their retroviral promoter, which is often used to control the expression of a heterologous (therapeutic) gene, is active in a wide range of different cell types.

- Retroviral vectors can be constructed to function as infectious particles or
- 15 to undergo a single round of transfection. In the former case, the virus is modified to retain all of its genes except for those responsible for oncogenic transformation properties, and to express the heterologous gene. Non-infectious viral vectors are manipulated to destroy the viral packaging signal from the genes encoding viral structural proteins, retaining the structural genes required to package the co-introduced virus engineered to
- 20 contain the heterologous gene and the packaging signals. Thus, the viral particles that are produced are not capable of producing additional virus.

- Packaging cell lines contain the genes for retrovirus replication and assembly, *e.g.*, gag, pol, and/or env. When transfected with a retroviral genome containing a gene of interest and assembly signals, the packaging cells become producer
- 25 cells. Suitable packaging cell lines have been described in the prior art, in particular the cell line PA317 (U.S. Patent No. 4,861,719); the PsiCRIP cell line (PCT Publication No. WO 90/02806) and the GP+envAm-12 cell line (PCT Publication No. WO 89/07150). In addition, the recombinant retroviral vectors can contain modifications within the LTRs for suppressing transcriptional activity as well as extensive encapsidation sequences which
- 30 may include a part of the *gag* gene (Bender *et al.*, J. Virol., 1987, 61:1639). Recombinant retroviral vectors are purified by standard techniques known to those having ordinary skill in the art.

**Lentivirus vectors.** Lentiviral vectors, which are a particular type of retrovirus vector, have also been used as agents for the direct delivery and sustained expression of a transgene in several tissue types, including brain, retina, muscle, liver, and blood. The vectors can efficiently transduce dividing and nondividing cells in these  
 5 tissues, and maintain long-term expression of the gene of interest. For a review, *see*, Naldini (Curr. Opin. Biotechnol., 1998, 9:457-63; *see also* Zufferey, *et al.*, J. Virol., 1998, 72:9873-80). Lentiviral packaging cell lines are available and known generally in the art. They facilitate the production of high-titer lentivirus vectors for gene therapy. An example is a tetracycline-inducible VSV-G pseudotyped lentivirus packaging cell line that can  
 10 generate virus particles at titers greater than  $10^6$  IU/ml for at least 3 to 4 days (Kafri, *et al.*, J. Virol., 1999, 73: 576-584). The vector produced by the inducible cell line can be concentrated as needed for efficiently transducing non-dividing cells *in vitro* and *in vivo*.

However, despite this impressive record, there is still a great need for the development of new, improved retroviral vectors and packaging systems to fuel further  
 15 advances in the field of human gene therapy.

### Structure of a Retroviral Vector

Retroviral vectors are infection-competent viral particles that contain functional packaging signals and a crippled genome in which most or all of the retroviral  
 20 protein coding sequences have been replaced with the gene(s) of interest. As a result, upon infection of a target cell, such viruses cannot undergo more than one round of replication in the absence of a helper virus. Retroviral vector particles are produced by helper cells (also called producer cells), which contain constructs expressing all retroviral proteins necessary for particle production and replication (*i.e.*, at least three proteins: gag,  
 25 pol, and env). After the introduction (transfection) of the RNA genome of a retroviral vector into such helper cells, it becomes encapsulated into virus particles (due to the presence of specific packaging signals in its RNA) having a complete set of retroviral proteins sufficient to support infection and a single round of replication and carrying a genome containing gene(s) of interest, and the packaging signals required to incorporate  
 30 the genome into the viral particle. Upon their release from the helper cells, the retroviral vector particles can be isolated from the culture medium and used to infect (transduce) various types of target cells. Following transduction, the RNA genome is reverse

transcribed into DNA and the DNA copy (provirus) is integrated into the host genome.

Safe and efficient retroviral-mediated gene transfer systems that are suitable for somatic gene therapy are likely to involve the development of alternative, cell type-targeted vectors containing the cell type-specific retroviral envelope protein (*env*), which, together with the availability of its cognate receptor, determines infectivity. Cell type targeting may be also achieved by using cell-specific promoters to limit the induction of expression of retroviral vector-encoded genes (for review *see* Gunzburg *et al.*, Cytokines Mol. Ther., 1996, 2:177-84).

### Use of Stem Cells for Retrovirus-Mediated Gene Delivery

The potential use of gene-modified repopulating stem cells as vehicles for retrovirus-mediated gene delivery was first illustrated by the demonstration that hematopoietic systems of lethally irradiated mice can be reconstituted with retroviral vector-transduced syngenic bone marrow cells, and that these cells can, in turn, provide genetically marked progeny, which persist in blood and marrow over extended periods of time (Chu *et al.*, J. Mol. Med., 1998, 76:184-92; Medin and Karlsson, Immunotechnology, 1997, 3:3-19).

The ability to transfer genes into stem cells of hematopoietic, neural or muscular origin would provide an opportunity for somatic gene therapy of various malignant and non-malignant disorders. Thus, gene transfer to primary hematopoietic cells may be used to treat diseases that affect bone marrow and peripheral blood function (for reviews *see* Anderson, Science, 1984, 226:401-409; Sorrentino *et al.*, pp. 351-426, *In: The Development of Gene Therapy*, T. Friedmann ed., New York: Cold Spring Harbor Laboratory Press, 1999). Examples of genetic diseases which are potentially curable by transgene-mediated delivery of a normal gene product include: X-linked agammaglobulinemia (Vetrie *et al.*, Nature, 1993, 361:226; Tusukada *et al.*, Cell, 1993, 72:279), ADA deficiency (Anderson, Science, 1992, 256:808), hemophilia (factor VIII and factor IX deficiency) (Miller, Blood, 1990, 76:271; Hoeben *et al.*, Thromb. Haemost., 1992, 67:341; Hoeben *et al.*, Hum. Gene Ther., 1993, 4:179; Herzog and High, Curr. Opin. Hematol., 1998, 5:321-6), and lipoprotein lipase deficiency (Hayden and Ma, Mol. Cell. Biochem., 1992, 113:171; Auwerx *et al.*, Crit. Rev. Clin. Lab. Sci., 1992, 29:243). Indeed, transfer of the gene coding for glucocerebrosidase (GC) via a retroviral vector (MFG-GC)

to human CD34 cells obtained from patients with Gaucher's disease was shown to result in correction of the enzyme deficiency in these cells (Barranger *et al.*, Baillieres Clin. Haematol., 1997, 10:765-78). Similarly, hematopoietic stem cells are an attractive target for gene therapy of AIDS because of their ability to generate a broad repertoire of mature T lymphocytes, as well as the monocytic cells (macrophages, dendritic cells and microglia), which are also involved in HIV-1 pathogenesis. A number of synthetic "anti-HIV-1 genes" have been developed which inhibit HIV-1 replication (Engel and Kohn, Front. Biosci., 1999, 4:e26-33). Gene transfer approaches can be also used in diagnosis and treatment of cancer, *e.g.*, to "mark" cancer cells to monitor their persistence *in vivo* in patients, to protect normal cells from toxic chemotherapeutic agents, to correct a genetic defect in or to confer a novel function on the cancer cell (Clay *et al.*, Pathol. Oncol. Res., 1999, 5:3-15). For example, preliminary experiments in transgenic mice have demonstrated that overexpression of the human multidrug resistance 1 (MDR1) gene results in a complete protection against high doses of cytostatic drugs (Fruehauf *et al.*, Recent Results Cancer Res., 1998, 144:93-115).

Several gene therapy protocols involving retroviral-vector-mediated transfer of exogenous genes into cells of hematopoietic lineage are in clinical trials. These include the introduction of the adenosine deaminase (ADA) gene into peripheral blood T cells of ADA deficient, severe combined immunodeficiency (SCID) patients (Sprent, Cell. Immunol., 1983, 7:10; Stevens *et al.*, J. Immunol., 1982, 128:844), and the introduction of marker genes or lymphokine genes into tumor infiltrating (TIL) T cells (Kasis *et al.*, Proc. Natl. Acad. Sci. USA, 1990, 87:473; Culver *et al.*, 1991, *ibid.*, 88:3155).

### **Existing Problems in Retroviral-Mediated Gene Transfer to Stem Cells**

Extensive efforts have been invested in adapting oncoretroviral vectors for gene transfer into stem cells (Allay *et al.*, Nat. Med., 1998, 4:1136-1143; Bunting *et al.*, Nat. Med., 1998, 4:58-64; Persons *et al.*, Nat. Med., 1998, 4:1201-1205; Donahue *et al.*, Blood, 2000, 95:445-452; Dunbar *et al.*, Blood, 1995, 85:3048-3057; Kiem *et al.*, Blood, 1998, 92:1878-1886). Despite considerable success in murine models, retroviral-mediated gene transfer into human stem cells has been difficult to achieve due to low abundance of viral receptors, inhibition of retroviral transgene expression, and the relative quiescence of the target cell population (Kurre *et al.*, J. Virol., 1990, 73:495-500; Miller *et al.*, Mol. Cell

Biol., 1990, 10:4239-4242; Orlic *et al.*, Proc. Natl. Acad. Sci. USA, 1996, 93:11097-11102; Bhatia *et al.*, J. Exp. Med., 1997, 186:619-624; Glimm *et al.*, Blood, 1999, 94:2161-2168.; Hao *et al.*, Blood, 1996, 88:3306-3313). As explained above, the latter problem can be solved by the use of lentiviral vectors, which are able to infect non-

5 dividing cells. In addition, the recent evidence suggests that repopulating hematopoietic stem cells can be induced to divide in short-term cultures with high concentrations of cytokines (Bhatia *et al.*, *supra*; Glimm H, *et al.*, *supra*), thus opening the possibility to increase the efficiency of oncoviral-mediated transduction. However, upon stimulation these stem cells are likely to differentiate, thus defeating the goal of using them in the first

10 place.

It appears therefore that the retroviral receptor deficiency and the efficiency and persistence of retroviral transgene expression are the major remaining barriers to stem cell-targeted gene transfer.

Another factor which has complicated the development of stem cell-

15 targeted gene therapy approaches for human disorders is the lack of reliable *in vitro* surrogate assays for the repopulating cells. Thus, successful gene transfer into hematopoietic progenitors, as evaluated in *in vitro* clonogenic assays, has been a poor predictor of long-term gene transfer into repopulating stem cells in large animal models or human clinical trials (Dunbar *et al.*, *supra*). Cells capable of initiating long-term culture

20 (LTC-IC), particularly those which give rise to hematopoietic progenitors over 10-12 weeks, may be a much better surrogate for repopulating stem cells (Hao *et al.*, *supra*; Sutherland *et al.*, Proc. Natl. Acad. Sci. USA, 1990, 87:3584-3588). Another surrogate for stem cell targeted gene transfer are the primitive human hematopoietic cells that are able to establish hematopoiesis in immunodeficient mice, such as the non-obese diabetic/severe

25 combined immunodeficiency (NOD/SCID) mouse strain. Human NOD/SCID repopulating cells (SRC) become engrafted in various hematopoietic cell lineages and can be recovered from murine bone marrow months after transplantation (Kamel-Reid *et al.*, Science, 1988, 242:1706- 1709; Vormoor *et al.*, Blood, 1994, 83:2489-2497; Cashman *et al.*, Blood, 1997, 89:4307- 4316; Larochelle *et al.*, Nat. Med., 1996, 2:1329-1337). It

30 follows that gene transfer strategies resulting in retroviral marking of a significant proportion of the progeny of SRC would be a better predictor for stem cell gene transfer than surrogates evaluated by *in vitro* assays (Larochelle *et al.*, Nat. Med., 1996, 2:1329-

1337).

Most vector preparations utilized for gene transfer into human cells contain particles having amphotropic specificity based on the structure of their envelope protein. Amphotropic viral particles have a broad host range that includes human cells (Kurre *et al.*, J. Virol., 1999, 73:495-500). In contrast, ecotropic vector particles used for gene transfer into murine stem cells are unable to transduce human cells because of interspecies polymorphic variation in the cationic transporter which serves as the receptor for ecotropic vector particles (Albritton *et al.*, J. Virol., 1993, 67:2091-2096; Kizhatil *et al.*, J. Virol., 1997, 71:7145-7156). Despite their broad cell type specificity, amphotropic vector particles infect human hematopoietic stem cells very inefficiently. It has been recently demonstrated that amphotropic vector particles enter their target cells via interactions with a phosphate transporter (van Zeijl *et al.*, Proc. Natl. Acad. Sci. USA, 1994, 91:1168-1172; Miller *et al.*, Proc. Natl. Acad. Sci. USA, 1994, 91:78-82; Kavanaugh *et al.*, Proc. Natl. Acad. Sci. USA, 1994, 91:7071-7075), which is expressed at very low levels on primitive human hematopoietic cells (Orlic *et al.*, *supra*) and possibly other types of stem cells. To overcome this barrier to retroviral-mediated gene transfer, vector preparations pseudotyped with envelope proteins from other viruses have been generated and studied.

Oncoretroviral vectors pseudotyped with the envelope protein of the Gibbon Ape Leukemia Virus (GALV) were shown to transduce human clonogenic hematopoietic progenitor cells (Bauer *et al.*, Blood, 1995, 86:2379-2387) and NOD/SCID repopulating cells (SRC) from cord blood more efficiently than amphotropic vector particles (van Hennik *et al.*, Blood, 1998, 92:4013-4022; Marandin *et al.*, Hum. Gene Ther., 1998, 9:1497-1511; Conneally *et al.*, Blood, 1998, 91:3487-3493). In accord with these data, the GALV receptor, also a phosphate transporter, was found to be expressed at a somewhat higher level than the amphotropic receptor (Kiem *et al.*, Blood, 1998, 92:1878-1886; Bauer *et al.*, Blood, 1995, 86:2379-2387). Thus, in studies in the NOD/SCID model, approximately 25% of human CD45<sup>+</sup> cells in multiple hematopoietic lineages of transplant recipients were positive for the vector genome as documented by PCR or transgene expression only after multiple exposures to viral vectors (van Hennik *et al.*, *supra*; Marandin *et al.*, *supra*; Schilz *et al.*, Blood, 1998, 92:3163-3171; Hennemann *et al.*, Experimental Hematology, 1999, 27:817-825). These data correlate with the results of larger animal studies in which GALV pseudotyped oncoretroviral vector particles show



higher frequency of gene transfer than amphotropic vector particles and are incorporated into 10% of myeloablated canine and baboon models (Kiem *et al.*, Blood, 1998, 92:1878-1886; Tisdale *et al.*, Blood, 1998, 92:1131-1141; Sellers *et al.*, Hum. Gene Ther., 1999, 10:633-640; Whitwam *et al.*, Blood, 1998, 92:1565-1575).

- 5                   The G envelope protein of vesicular stomatitis virus (VSV-G), a rhabdovirus, has been used to pseudotype both lentiviral and oncoviral vector particles (Yang *et al.*, Hum. Gene Ther., 1995, 6:1203-1213; Emi *et al.*, J. Virol., 1991, 65:1202-1207; Friedmann *et al.*, Nat. Med., 1995, 1:275-277; Akkina *et al.*, J. Virol., 1996, 70:2581-2585; Naldini *et al.*, Science, 1996, 272:263-267). The VSV-G pseudotyped
- 10 particles can be concentrated 100-1,000 fold by centrifugation and they enter target cells via interaction with phospholipids which are found on all cell types (Burns *et al.*, Proc. Natl. Acad. Sci. USA, 1993, 90:8033-8037). It has been shown that both VSV-G pseudotyped oncoviral and lentiviral vector particles efficiently transduce hematopoietic stem cells (Evans *et al.*, Hum. Gene Ther., 1999, 10:1479-1489; Douglas *et al.*, Hum.
- 15 Gene Ther., 1999, 10:935-945; Case *et al.*, Proc. Natl. Acad. Sci. USA, 1999, 96: 2988-2993; Sinclair *et al.*, Gene Ther., 1997, 4:918-927). Successful gene transfer into SRC using VSV-G pseudotyped oncoretroviral or lentiviral vector particles has been also reported (Rebel *et al.*, Blood, 1999, 93:2217-2224; Miyoshi *et al.*, Science, 1999, 283:682-686). Despite the increased efficiency of gene transfer observed with VSV-G pseudotyped
- 20 particles compared with GALV pseudotyped and amphotropic vector particles, the use of these particles for therapeutic purposes is questionable. VSV-G protein is toxic to producer cells by causing the membrane fusion, and the inducible promoters must be used to control its expression (Yang *et al.*, *supra*; Ory *et al.*, Proc. Natl. Acad. Sci. USA, 1996, 93:11400-11406).
- 25                   Vector particles pseudotyped with the envelope protein of the feline endogenous virus RD114 have been described (U.S. Patent No. 5,952,225). The RD114 retrovirus is a member of the large interference group 1 of retroviruses all of which use the same receptor on human cells (Sommerfelt *et al.*, Virology, 1990, 176:58-69) recently identified as a neutral amino acid transporter (Rasko *et al.*, Proc. Natl. Acad. Sci. USA,
- 30 1999, 96:2129-2134). In addition, murine RD114 pseudotyped vector particles have been shown transduce human hematopoietic cells at about the same efficiency as amphotrophic vector, when the target cells were cultured with the producer cell line (Porter *et al.*, Hum.

Gene Ther., 1996, 7:913-919; Rasko *et al.*, Proc. Natl. Acad. Sci. USA, 1999, 96:2129-2134). However, in practice it is highly undesirable to co-culture the target cells with the producer cells as this is not considered a Good Manufacturing Process. Indeed, one cannot regard the results of this experiment with high confidence. Using this approach, the level  
5 of transduction was only the same as with amphotropic viral particles, which indicates that the method does not correlate with previously noted *in vitro* data.

Thus, there is a clear need in the art for more efficient, and thus cost effective, *ex vivo* transduction of stem cells. There is a further need for *ex vivo* transduction of stem cells without inducing stem cell differentiation. The present  
10 invention advantageously addresses these and other needs in the art.

The citation of any reference herein should not be construed as an admission that such reference is available as prior art to the instant invention.

15

### **SUMMARY OF THE INVENTION**

The invention provides a highly efficient method for transducing stem cells with a vector particle, particularly a retroviral vector particle, containing a gene of interest, e.g., in a modified retroviral genome. This method comprises contacting target cells with  
20 vector particles pseudotyped with feline endogenous virus RD114 envelope protein (including binding fragments and fusion proteins) and containing a gene of interest. A feature of the invention is that the vector particles are substantially free of producer cells and producer cell supernatant. Thus, high efficiency transduction of the invention is consistent with Good Manufacturing Practices and avoids conditions that are likely to  
25 induce stem cell differentiation. The advantages of the invention can be achieved by using artificial RD114 pseudotyped particles, by pre-adsorbing the retroviral particles onto a surface that promotes adherence of the retroviral particles, or by freeing the viral particles of producer cells and producer cell supernatant by ultracentrifugation, or both of the latter two.

30

According to the disclosed method, the target stem cells are pre-stimulated by treatment with signaling molecules selected from the group consisting of cytokines, growth factors and phytohemagglutinin.

progenitor cells derived from primitive hematopoietic cells. Such cells can be cord blood cells, mobilized peripheral blood cells, bone marrow cells, and liver cells. Preferably they are CD34<sup>+</sup> cells; more preferably they are CD34<sup>+</sup>,CD38<sup>-</sup> cells.

The invention further provides a population of stem cells transduced with  
 5 vector particles, particularly retroviral vector particles, pseudotyped with feline endogenous virus RD114 envelope protein and containing a gene of interest. The population of stem cells are substantially undifferentiated. Upon engraftment of the transduced stem cells contacted one time with the retroviral particles into a host, greater than 10% of the transduced cells can express the gene of interest. In a more specific  
 10 embodiment, greater than about 40% of the transduced cells express the gene of interest. These are remarkable results.

In addition, the invention provides a method for introducing a gene of interest into a host. This method comprises introducing the population of transduced stem cells of the invention into a host, *e.g.*, a human (and the stem cells are human stem cells), a  
 15 non-human host (when the stem cells are autologous or syngenic to the non-human host), or an immunodeficient animal (and the stem cells are human stem cells). Preferably, greater than about 40% of the engrafted transduced stem cells express the gene of interest.

Thus, the invention further provides a non-human animal engrafted with the transduced stem cells of the invention, such as an immunodeficient mouse or a monkey.

20 The invention further provides a method of treating a disease or disorder, which method comprises administering to a patient a therapeutically effective dose of the population of transduced stem cells of the invention, wherein the gene of interest is a therapeutic gene.

A kit comprising retroviral vector particles pseudotyped with feline  
 25 endogenous virus RD114 envelope protein and containing a gene of interest their genome pre-adsorbed onto a surface that promotes adherence of the retroviral particles, wherein the retroviral vector particles are substantially free of producer cells and producer cell supernatant, is also provided.

Also, a method for preparing the kit is disclosed. This method comprises  
 30 contacting the surface with the retroviral vector particles for a sufficient period of time to permit adherence of the retroviral particles to the surface, and removing supernatant in which the retroviral particles were suspended from the surface. The invention

advantageously permits storing the retroviral particles adsorbed onto the surface, *e.g.*, at -70°C.

### **DETAILED DESCRIPTION OF THE INVENTION**

5           The present invention relates to a method for efficiently introducing exogenous genes into stem cells which, in turn, leads to introducing the exogenous genes into cell lineages derived from these stem cells. Moreover, the high efficiency transduction achieved in accordance with this invention can be achieved without inducing stem cell differentiation. The invention is based, in part, on the discovery that RD114  
10 pseudotyped retroviral vectors efficiently transduce hematopoietic stem cells due to unique properties and stability of the vector preparations. These properties include the unexpected ability to highly concentrate RD114 envelope pseudotyped retroviral vectors by adsorbing it on a surface or by ultracentrifugation, thus permitting more effective transduction free of producer cells and producer cell supernatant. Thus, advantages of the  
15 present invention are due to the unique, and previously unknown (as well as unexpected) properties of RD114 pseudotyped retroviruses.

          The term "vector particle" refers to a retroviral vector particle or an artificial particle, such as a liposome, protein matrix, or other gene transfer particle (described in greater detail, *infra*) that contains genetic material for transfer into and expression in a cell.  
20 The genetic material can be a modified retroviral genome or a recombinant DNA or RNA construct.

          As used herein, "retroviral vector" and "retroviral vector particle" refer to a modified retroviral genome that contains a heterologous or exogenous gene of interest within the retroviral packaging signals, that has been incorporated within a retroviral  
25 particle assembled by a producer cell. The retroviral particles of the present invention contain an RD114 envelope (*env*) protein; thus, they are RD114-pseudotyped retroviral particles.

          As one of ordinary skill in the art would appreciate, the term "pseudotyped with feline endogenous virus RD114 envelope protein" means that the vector particle  
30 contains an RD114 protein, or the N-terminal segment of the protein involved in binding, so that the vector particle demonstrates binding properties of RD114. The RD114 protein or binding portion can be included in a fusion construct.

By "highly efficient", the present invention contemplates significant improvements over the efficiency of stem cell transduction previously reported. It should be noted that efficiency as used herein refers to transduction of stem cells capable of expressing the transgene (the gene of interest) *in vivo*; *in vitro* transduction efficiencies can be very high, for example on the order of 90%. The only level of transduction efficiency that has any relevance is long term marking in hosts, particularly humans and large animals, like the rhesus monkey. However, the highest level of transduction efficiency reported *in vivo* (*i.e.*, after engraftment of the cells transduced *ex vivo*), has been reported to be less than 10% per number of exposures to (*i.e.*, times contacted with) transducing retroviral vectors, as discussed above. The best level of transduction efficiency of which the inventors are aware in a relevant model is no more than 10%. In a specific embodiment, the present invention permits transduction efficiency of about 40% after a single transduction step (contacting the target stem cells with the retroviral vector preparation one time). When considered at the level of the best single animal, the prior art has reported 71% engraftment (in mice), compared to the present invention with an efficiency exceeding 90% in individual animals.

High efficiencies of the invention are achieved by contacting the stem cells with retroviral vector particles pre-adsorbed onto a surface. In a preferred embodiment, the single exposure of stem cells to the pre-adsorbed retroviral particles results in very high levels of transduction efficiency. Higher levels still can be achieved by supplying additional retroviral particles. In order to preserve the phenotype of the target stem cells, the amount of producer cell supernatant added with this second exposure to retroviral particles should be minimized. An advantage of the present invention is the discovery that the RD114 env protein permits concentration of the retroviral particles by ultracentrifugation. Thus, a second exposure or contacting step of the stem cells with retroviral particles is preferably achieved with ultracentrifuge-concentrated retroviral particles.

The term "*ex vivo*" is used herein to refer to transduction of target stem cells with a retroviral vector of the invention in a culture system outside of the host, followed by administration of the transduced stem cells into the host, *i.e.*, engraftment of the transduced stem cells. This term is used in contrast to *in vitro*, which only refers to transduction and maintenance of target cells in tissue culture, and *in vivo*, in which the

vector is administered to the host animal for transduction of the endogenous cells.

As used herein, the term "stem cells" includes but is not limited to hematopoietic stem cells, neural stem cells, mesenchymal (particularly muscular) stem cells, and liver stem cells. Stem cells are capable of repopulating tissue(s) *in vivo*.

5 Hematopoietic stem cells are progenitor cells derived from primitive human hematopoietic cells. In a specific embodiment, *infra*, for gene transfer into hematopoietic stem cells, the target cells are selected from the group consisting of cord blood cells, mobilized peripheral blood cells, bone marrow cells, and liver cells. The cells best able to repopulate hematopoietic tissues are CD34<sup>+</sup> cells, and preferably CD34<sup>+</sup>,CD38<sup>-</sup> cells. "Mesenchymal  
10 stem cells" refer to the cells isolated from connective tissue, including muscle and dermis, which have the ability to differentiate into several phenotypes of the mesodermal lineage, including cartilage and bone (*see* U.S. Patent Nos. 5,906,934, 5,827,735, and 5,486,359). The term "target" is used to indicate that the retroviral vector is intended to transduce the cells.

15 A stem cell "population" refers to the stem cells following contact with and transduction by the retroviral vector; because not every stem cell is transduced or transduced effectively (such that it expresses the transgene after engraftment), the cells constitute a heterogeneous population, hence use of that term. While it is possible to isolate or purify the transduced cells (*e.g.*, by including a selection marker in the retroviral  
20 vector genome), that is not necessary in the practice of the invention (and, indeed, to the extent that extraneous genes and gene products, including selection genes, are undesirable when the transduced cells are engrafted into a human host for a gene therapy, such markers are preferably avoided).

The novel gene transfer method of the instant invention involves the use of  
25 the retroviral vector (also referred to herein as "retroviral vector particles") pseudotype with feline endogenous virus RD114 envelope protein. As disclosed in specific embodiments, these RD114 pseudotyped retroviral vector particles are generated from producer cells which comprise: (i) a polynucleotide encoding a minimal *gag-pol* open reading frame (ORF) and expressing gag and pol proteins; (ii) a polynucleotide encoding a  
30 minimal ORF of feline endogenous virus RD114 envelope protein (*env*); (iii) a retroviral vector including a 5' LTR, a 3' LTR, a packaging signal, and a gene of interest encoding a protein or polypeptide of interest under control of an appropriate expression control

sequence ("vector genome"). It follows that the retroviral vector particles employed in the present invention contain in their genome only the heterologous coding sequences or sequences and the signals needed for particle assembly (packaging). These vectors can efficiently replicate to produce infective virus only in the producer (helper) cells (which  
 5 supply gag, pol and env proteins), and undergo a single cycle of replication and insertion upon infecting a target cell.

The retroviral vector particles are "substantially free of factors that induce stem cell differentiation" when they are substantially free of producer cells and producer cell supernatant, or when the packaging cells do not themselves produce differentiation  
 10 factors that affect the stem cells, or when the producer cell culture fluid is treated to neutralize or remove any such factors, *e.g.*, with inhibitory antibodies or by immunoprecipitation. The retroviral vector particles are "substantially free of producer cells and producer cell supernatant" when they have been isolated from the producer cell culture in which they were produced. The term "substantially" with respect to the  
 15 producer cells means that the presence of producer cells cannot be detected by microscopy, more preferably by immunoassay, more preferably still by nucleic acid hybridization (Northern or Southern hybridization), and most preferably by nucleic acid amplification, *e.g.*, by polymerase chain reaction (PCR). The term substantially with respect to culture fluid means that the amount of differentiation-inducing factor in producer cell culture fluid  
 20 present is too low to cause the stem cells to differentiate, proliferate, die, or undergo any other undesirable outcome. In a specific embodiment, substantially free of producer cell culture fluid means that, when contacted with the target stem cells, less than about 10% of the culture fluid in which the stem cells are suspended is producer cell culture fluid; preferably less than about 1%; and more preferably less than about 0.1%.

25 In specific embodiments, the producer cells of the present invention are derived from HT1080 human sarcoma cell line (ATCC CCL-121), 293T human embryonic kidney cell line (ATCC CRL-1573), or NIH 3T3 mouse fibroblast cell line (ATCC CRL-1658), to mention a few possibilities. The retroviral vector particles can be found in the producer cell culture fluid, which is the culture medium in which the producer  
 30 cells grow and effectively permit retroviral vector replication and production.

According to the invention, the retroviral vector particles can be oncoviral particles or lentiviral particles. In a specific embodiment, the RD114 pseudotyped

oncoviral vector genome is derived from murine leukemia virus (MLV). In another specific embodiment, the RD114 pseudotyped oncoviral vector genome is derived from mouse stem cell virus (MSCV). The present invention also discloses the generation of HIV-1-based RD114 pseudotyped lentiviral vector particles. In each of these cases, the key element is using an RD114 *env* gene in the producer cell.

As used herein, the term "isolated" means that the referenced material is free of components found in the natural environment in which the material is normally found. In particular, isolated biological material is free of cellular components. In the case of nucleic acid molecules, an isolated nucleic acid includes a PCR product, an isolated mRNA, a cDNA, or a restriction fragment. In another embodiment, an isolated nucleic acid is preferably excised from the chromosome in which it may be found, and more preferably is no longer joined to non-regulatory, non-coding regions, or to other genes, located upstream or downstream of the gene contained by the isolated nucleic acid molecule when found in the chromosome. In yet another embodiment, the isolated nucleic acid lacks one or more introns. Isolated nucleic acid molecules can be inserted into plasmids, cosmids, artificial chromosomes, and the like. Thus, in a specific embodiment, a recombinant nucleic acid is an isolated nucleic acid. An isolated protein may be associated with other proteins or nucleic acids, or both, with which it associates in the cell, or with cellular membranes if it is a membrane-associated protein. An isolated organelle, cell, or tissue is removed from the anatomical site in which it is found in an organism. An isolated material may be, but need not be, purified.

The term "purified" as used herein refers to material that has been isolated under conditions that reduce or eliminate unrelated materials, *i.e.*, contaminants. For example, a purified protein is preferably substantially free of other proteins or nucleic acids with which it is associated in a cell; a purified nucleic acid molecule is preferably substantially free of proteins or other unrelated nucleic acid molecules with which it can be found within a cell. As used herein, the term "substantially free" is used operationally, in the context of analytical testing of the material. Preferably, purified material substantially free of contaminants is at least 50% pure; more preferably, at least 90% pure, and more preferably still at least 99% pure. Purity can be evaluated by chromatography, gel electrophoresis, immunoassay, composition analysis, biological assay, and other methods known in the art.



The phrase "pharmaceutically acceptable", whether used in connection with the pharmaceutical compositions of the invention or vaccine compositions of the invention, refers to molecular entities and compositions that are physiologically tolerable and do not typically produce untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin, 18<sup>th</sup> Edition.

The term "about" or "approximately" will be known to those skilled in the art in light of this disclosure. Generally it means that a particular value can range within an acceptable error for the type of measurement from which the value is obtained. For example, the term can mean within 20%, more preferably within 10%, and more preferably still within 5% of a given value. Alternatively, especially in biological systems, the term "about" preferably means within about a log (*i.e.*, an order of magnitude), preferably within a factor of five and more preferably within a factor of two, of a given value, depending on how quantitative the measurement.

## 25 Molecular Biology - Definitions

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, *e.g.*, Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook *et al.*, 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II (D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid*

- (D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization*, B.D. Hames & S.J. Higgins eds. (1985); *Transcription And Translation*, B.D. Hames & S.J. Higgins, eds. (1984); *Animal Cell Culture*, R.I. Freshney, ed. (1986); *Immobilized Cells And Enzymes*, IRL Press, (1986); B. Perbal, *A Practical Guide To*
- 5 *Molecular Cloning* (1984); F.M. Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc. (1994).

A "coding sequence" or a sequence "encoding" an expression product, such as a RNA, polypeptide, protein, or enzyme, is a nucleotide sequence that, when expressed, results in the production of that RNA, polypeptide, protein, or enzyme, *i.e.*, the nucleotide

10 sequence encodes an amino acid sequence for that polypeptide, protein or enzyme. A coding sequence for a protein may include a start codon (usually ATG) and a stop codon.

The term "gene", also called a "structural gene" means a DNA sequence that codes for or corresponds to a particular sequence of amino acids which comprise all or part of one or more proteins, and may or may not include regulatory DNA sequences, such

15 as promoter sequences; that determine for example the conditions under which the gene is expressed. The transcribed region of a gene can include 5'- and 3'-untranslated regions (UTRs) and introns in addition to the translated (coding) region. As used herein, the term "gene" in conjunction with a vector means a coding sequence operatively associated with an expression control sequence; it can therefore be an artificial construct.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate

20 transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.

Promoters that may be used to control gene expression include, but are not

30 limited to, cytomegalovirus (CMV) promoter (U.S. Patent Nos. 5,385,839 and 5,168,062), the SV40 early promoter region (Benoist and Chambon, *Nature*, 1981, 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, *et*

- Natl. Acad. Sci. U.S.A., 1981, 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster *et al.*, Nature, 1982, 296:39-42); prokaryotic expression vectors such as the  $\beta$ -lactamase promoter (Villa-Komaroff, *et al.*, Proc. Natl. Acad. Sci. U.S.A., 1978, 75:3727-3731), or the *tac* promoter (DeBoer, *et al.*, Proc. Natl. Acad. Sci. U.S.A., 1983, 80:21-25); *see also* "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter; and transcriptional control regions that exhibit hematopoietic tissue specificity, in particular: beta-globin gene control region
- 10 which is active in myeloid cells (Mogam *et al.*, Nature, 1985, 315:338-340; Kollias *et al.*, 1986, Cell 46:89-94), hematopoietic stem cell differentiation factor promoters, erythropoietin receptor promoter (Maouche *et al.*, Blood, 1991, 15:2557), etc.

- A coding sequence is "under the control" of or "operably associated with" transcriptional and translational control sequences in a cell when RNA polymerase
- 15 transcribes the coding sequence into mRNA, which is then trans-RNA spliced (if it contains introns) and translated into the protein encoded by the coding sequence.

- The terms "express" and "expression" mean allowing or causing the information in a gene or DNA sequence to become manifest, for example producing a protein by activating the cellular functions involved in transcription and translation of a
- 20 corresponding gene or DNA sequence. A DNA sequence is expressed in or by a cell to form an "expression product" such as an mRNA or a protein. The expression product itself, *e.g.* the resulting mRNA or protein, may also be said to be "expressed" by the cell. An expression product can be characterized as intracellular, extracellular or secreted. The term "intracellular" means something that is inside a cell. The term "extracellular" means
- 25 something that is outside a cell. A substance is "secreted" by a cell if it appears in significant measure outside the cell, from somewhere on or inside the cell. "Conditions that permit expression", *in vitro* are culture conditions of temperature (generally about 37°C), humidity (humid atmosphere), carbon dioxide concentration to maintain pH (generally about 5% CO<sub>2</sub> to about 15% CO<sub>2</sub>), pH (generally about 7.0 to 8.0, preferably
- 30 7.5), and culture fluid components, that depend on host cell type. *In vivo*, the conditions that permit expression are primarily the health of the animal, which depends on adequate nutrition, water, habitation, and environmental conditions (light-dark cycle, temperature,

humidity, noise level). In either system, expression may depend on a repressor or inducer control system, as well known in the art.

The term "transfection" means the introduction of a "foreign" (*i.e.* extrinsic or extracellular) gene, DNA or RNA sequence into a host cell, so that the host cell will  
 5 express the introduced gene or sequence to produce a desired substance, typically a protein or enzyme coded by the introduced gene or sequence. The introduced gene or sequence may also be called a "cloned" or "foreign" gene or sequence, may include regulatory or control sequences, such as start, stop, promoter, signal, secretion, or other sequences used by a cell's genetic machinery. The gene or sequence may include nonfunctional sequences  
 10 or sequences with no known function. A host cell that receives and expresses introduced DNA or RNA has been "transfected" and is a "transfectant" or a "clone." The DNA or RNA introduced to a host cell can come from any source, including cells of the same genus or species as the host cell, or cells of a different genus or species.

The terms "vector", "cloning vector" and "expression vector" mean the  
 15 vehicle by which a DNA or RNA sequence (*e.g.* a foreign gene) can be introduced into a host cell, so as to transform the host and promote expression (*e.g.* transcription and translation) of the introduced sequence. Vectors include plasmids, phages, viruses, etc.; they are discussed in greater detail below.

Retroviral vectors typically comprise the RNA of a transmissible agent, into  
 20 which a heterologous sequence encoding a protein of interest is inserted. Typically, the retroviral RNA genome is expressed from a DNA construct. A common way to insert one segment of DNA into another segment of DNA involves the use of enzymes called restriction enzymes that cleave DNA at specific sites (specific groups of nucleotides) called restriction sites. A "cassette" refers to a DNA segment that can be inserted into a  
 25 vector or into another piece of DNA at a defined restriction site. Preferably, a cassette is an "expression cassette" in which the DNA is a coding sequence or segment of DNA that codes for an expression product that can be inserted into a vector at defined restriction sites. The cassette restriction sites generally are designed to ensure insertion of the cassette in the proper reading frame. Generally, foreign DNA is inserted at one or more  
 30 restriction sites of the vector DNA, and then is carried by the vector into a host cell along with the transmissible vector DNA. A segment or sequence of DNA having inserted or added DNA, such as an expression vector, can also be called a "DNA construct." A

common type of DNA construct is a "plasmid" that generally is a self-contained molecule of double-stranded DNA, usually of bacterial origin, that can readily accept additional (foreign) DNA and which can be readily introduced into a suitable producer cell. A plasmid vector often contains coding DNA and promoter DNA and has one or more

5 restriction sites suitable for inserting foreign DNA. A large number of vectors, including plasmid and fungal vectors, have been described for replication and/or expression in a variety of eukaryotic and prokaryotic hosts. Non-limiting examples include pKK plasmids (Amersham Pharmacia Biotech), pUC plasmids, pET plasmids (Novagen, Inc., Madison, WI), pRSET or pREP plasmids (Invitrogen, San Diego, CA), or pMAL plasmids (New

10 England Biolabs, Beverly, MA), and many appropriate host cells, using methods disclosed or cited herein or otherwise known to those skilled in the relevant art. Recombinant cloning vectors will often include one or more replication systems for cloning or expression, one or more markers for selection in the host, *e.g.* antibiotic resistance, and one or more expression cassettes. A "retroviral plasmid vector" means a plasmid which

15 includes all or part of a retroviral genome including 5' and 3' retroviral long-term repeat (LTR) sequences, a packaging signal (.psi.), and may include one or more polynucleotides encoding a protein(s) or polypeptide(s) of interest, such as a therapeutic agent or a selectable marker. Such retroviral plasmid vectors are described, *e.g.*, in U.S. Patent No. 5,952,225 (column 4, line 5 to column 5, line8), which is specifically incorporated herein

20 by reference.

Synthetic vector particles can be prepared using lipofection technology, optionally with other transfection facilitating agents (peptides, polymers, etc.). Synthetic cationic lipids can be used to prepare liposomes for *in vivo* transfection of a gene (Felgner, et. al., Proc. Natl. Acad. Sci. USA 1987, 84:7413-7417; Felgner and Ringold, Science

25 1989, 337:387-388; see Mackey, *et al.*, Proc. Natl. Acad. Sci. USA 1988, 85:8027-8031; Ulmer *et al.*, Science 1993, 259:1745-1748). Useful lipid compounds and compositions for transfer of nucleic acids are described in PCT Publications WO95/18863 and WO96/17823, and in U.S. Patent No. 5,459,127. Lipids may be chemically coupled to

RD114 molecules for the purpose of targeting (see Mackey, et. al., *supra*), or by insertion

30 of an RD114 polypeptide construct into the lipid bilayer, *i.e.*, by analogy to a transmembrane protein.

The term "host" or "host animal" means any animal that is selected,

modified, engrafted, or manipulated in any way, for the production of the protein of interest (expressed by the gene of interest) in the host. Non-human animal hosts can further be used for screening or other assays, as described *infra*. Human hosts can be used to study the distribution and fate of engrafted stem cells, *e.g.*, carrying a marker gene.

5           The term "heterologous" refers to a combination of elements not naturally occurring. For example, heterologous DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. A heterologous expression regulatory element is such an element operatively associated with a different gene than the one it is operatively associated with in nature. In the context of the present invention, a coding sequence of  
10 interest is heterologous to the retroviral vector RNA in which it is inserted for expression, and it is heterologous to a host cell or animal containing such a vector in which it is expressed, *e.g.*, a CHO cell, a mouse, a monkey, or a human.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler *et al.*, Cell, 1977, 11:223),  
15 hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 1962, 48:2026), and adenine phosphoribosyltransferase (Lowy *et al.*, Cell, 1980, 22:817) genes can be employed in tk-, hgp<sup>r</sup>t-, or ap<sup>r</sup>t- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler *et al.*, Proc. Natl. Acad. Sci. USA,  
20 1980, 77:3567; O'Hare *et al.*, Proc. Natl. Acad. Sci. USA, 1981, 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 1981, 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin *et al.*, J. Mol. Biol., 1981, 150:1); and hyg<sup>r</sup>, which confers resistance to hygromycin (Santerre *et al.*, Gene, 1984, 30:147).

25           One aspect of the invention involves the use of a retroviral vector genome expressing a bicistronic transcript encoding the gene of interest and a selectable marker gene, wherein the selectable marker gene is arranged downstream of the stop codon of the gene of interest and is separated from it by an internal ribosome entry site to insure that it is expressed from the corresponding mRNA as a result of translation reinitiation.

30           According to the invention, the inclusion of a selectable marker gene allows the efficient selection of producer cells and transduced target cells. Thus, in one embodiment, the present invention discloses the use of a selectable marker gene encoding a drug-resistant

variant of human dehydrofolate reductase which confers the resistance to trimetrexate. In another embodiment, the present invention discloses the use of retroviral vectors which do not encode a selectable marker, but only the gene(s) of interest.

5

### Use of the Vector Particles

According to the invention, the gene of interest carried by the RD114 can be any gene pseudotyped vector particle. In a preferred embodiment, the gene of interest is a therapeutically relevant gene. The non-limiting examples of such genes include genes encoding wild-type proteins missing in mutant cells (*e.g.*, factors VII and IX, tumor suppressor genes, etc.) and genes involved in drug resistance or anti-viral resistance (*e.g.*, MDR, ribozymes, antisense RNAs, anti-viral proteases, etc.). Examples of therapeutic genes include polynucleotides encoding tumor necrosis factor (TNF) genes, such as TNF- $\alpha$ ; genes encoding interferons such as Interferon- $\alpha$ , Interferon- $\beta$ , and Interferon- $\gamma$ ; genes encoding interleukins such as IL-1, IL- $\beta$ , and Interleukins 2 through 14; genes encoding GM-CSF; genes encoding adenosine deaminase, or ADA; genes which encode cellular growth factors, such as lymphokines, which are growth factors for lymphocytes; genes encoding epidermal growth factor (EGF), and keratinocyte growth factor (KGF); genes encoding soluble CD4; Factor VIII; Factor IX; cytochrome b; glucocerebrosidase; T-cell receptors; the LDL receptor, ApoE, ApoC, ApoAI and other genes involved in cholesterol transport and metabolism; the alpha-1 antitrypsin ( $\alpha$ 1AT) gene; the insulin gene; the hypoxanthine phosphoribosyl transferase gene; the CFTR gene; negative selective markers or "suicide" genes, such as viral thymidine kinase genes, *e.g.*, the Herpes Simplex Virus thymidine kinase gene, the cytomegalovirus virus thymidine kinase gene, and the varicella-zoster virus thymidine kinase gene; Fc receptors for antigen-binding domains of antibodies, antisense sequences which inhibit viral replication, such as antisense sequences which inhibit replication of hepatitis B or hepatitis non-A non-B virus; antisense c-myc oligonucleotides; anti-tumor protein intracellular antibodies; and antioxidants such as, but not limited to, manganese superoxide dismutase (Mn-SOD), catalase, copper-zinc-superoxide dismutase (CuZn-SOD), extracellular superoxide dismutase (EC-SOD), and glutathione reductase; tissue plasminogen activator (tPA); urinary plasminogen activator (urokinase); hirudin; the phenylalanine hydroxylase gene; nitric oxide synthetase; vasoactive peptides; angiogenic peptides; the dopamine gene; the

nitric oxide synthetase; vasoactive peptides; angiogenic peptides; the dopamine gene; the dystrophin gene; the  $\beta$ -globin gene; the  $\alpha$ -globin gene; the HbA gene; protooncogenes such as the ras, src, and bcl genes; tumor-suppressor genes such as p53 and Rb; the LDL receptor; the heregulin- $\alpha$  protein gene, for treating breast, ovarian, gastric and endometrial cancers; monoclonal antibodies specific to epitopes contained within the  $\beta$ -chain of a T-cell antigen receptor; the multidrug resistance (MDR) gene; polynucleotides encoding ribozymes; antisense polynucleotides; genes encoding secretory peptides which act as competitive inhibitors of angiotensin converting enzyme, of vascular smooth muscle calcium channels, or of adrenergic receptors, and polynucleotides encoding enzymes which break down amyloid plaques within the central nervous system. It is to be understood, however, that the scope of the present invention is not to be limited to any particular therapeutic agent. In one of the embodiments, the invention also discloses the use of a gene of interest encoding a marker gene, such as enhanced green fluorescent protein (EGFP). Such marker genes are particularly useful for tracking the fate of transduced cells, *e.g.*, during clinical development of a gene therapy based on the vectors and methods of the invention.

The present invention also discloses a method for somatic gene therapy which involves introducing a gene of interest contained within the vector particle, such as in a retroviral genome, into human repopulating stem cells followed by introducing these cells into a human host. Such therapies can be tested on the animal models described herein. In accord with the present invention, an animal model system is described for use in retroviral gene therapy studies, which employs an efficient and rapid protocol for the introduction of exogenous genes.

Because the vector particles of the invention are highly efficient at transducing stem cells, they are particularly attractive for somatic gene therapy. Gene therapy can be used to treat any disorders characterized by a defect in a single gene, or which can be treated by producing expression of a gene, even though the cause of the disease is a multi-genic defect, or some non-genetic cause, such as an infection or autoimmunity. In particular, diseases that can be treated with the invention, in addition to those set forth in the background of the invention or that are obvious from the foregoing list of therapeutic genes, are hematopoietic disease, neural disease, joint-related disease, muscular disease, and liver disease. In particular, joint-related diseases include



cells may be beneficial.

The present invention yet further discloses a method for monitoring the efficiency of the stem cell-mediated gene transfer based on detecting the presence of the genes (or the expression products) of the vector in various stem cell-derived lineages of the host. As disclosed in a specific embodiment, the presence of the genes of the vector can be monitored by any of the methods known in the art, but most preferably by PCR (using retroviral-specific primers) and/or by detecting the polypeptide product of the vector-encoded gene(s) (*e.g.*, using immunochemical or fluorescence assays).

The disclosed novel highly efficient method of vector particle-mediated transduction of stem cells preferably comprises the steps of : (i) optionally inducing the proliferation of a target stem cell by pre-stimulation; and (ii) incubating the pre-stimulated target stem cell with a vector particle containing a gene of interest and pseudotyped with feline endogenous virus RD114 envelope protein. While traditionally, the transduced cells are expanded in culture, the present invention advantageously omits this step, and thus avoids inducing stem cell differentiation. In a less preferred embodiment, the target stem cell is pre-stimulated with cytokines and/or growth factors. These cytokines and growth factors can be selected from the group consisting of but not limited to: stem cell factor, Flt-3 ligand, interleukin-2, interleukin-3, interleukin-6, and phytohemagglutinin. According to the method of the instant invention, the optimal efficiency of retroviral-stimulated stem cell transduction requires using target cell density around  $1-5 \times 10^4$  cells/cm<sup>2</sup> and is attained upon pre-stimulating target cells for 24-48 hours.

As pointed out above, the method of the present invention benefits from the use of RD114 pseudotyped retroviral vector particles substantially free of producer cells and producer cell supernatant. Such retroviral particles can be either pre-adsorbed on retronectin coated plates or concentrated by ultracentrifugation. As disclosed in a specific embodiment, HT1080-derived producer cells (and potentially other kinds of producer cells) contain in their medium an unidentified substance that induces phenotypic change in the target cells, leading to their elimination upon engraftment in the immunodeficient host. According to the method of the instant invention, retronectin-pre-adsorbed and ultrafiltration-concentrated retroviral particles and synthetic vector particles that contain RD114 binding polypeptides are free of contaminating and potentially harmful substances present in the culture media of producer cells, leading to the efficient transduction and

engraftment of the target cells without any change in their phenotype. In a preferred embodiment, the disclosed method involves producing retronectin plates with pre-adsorbed retroviral vector particles as a part of a transduction kit which can be stored at low temperatures for long periods of time.

5 As exemplified in examples below, cells can be transduced by the vector particles of the invention by direct contact in tissue culture. For example, in a specific embodiment, cells are exposed to pre-loaded vector (adsorbed to surfaces) at 48 hours in culture. Alternatively, concentrated vector can be added to these cells. In yet another alternative, the cells at 48 hours in culture are contacted with pre-loaded vector, and  
10 concentrated vector is added at 72 hours. While this latter addition results in contact or exposure to producer cell supernatant, the total amount of supernatant is limited. This is because ultracentrifugation concentrates the virus 50 to 100-fold, although the concentrated virus is in approximately 50% solution of supernatant. Adding this to the media containing the target stem cells at a 10% volume means exposing the cells to 5%  
15 producer cell supernatant. Presumably, as a result of centrifugation, most of the adverse proteins do not concentrate due to their small size. Thus, the target stem cells are exposed to less than 10% of the concentrated producer cell fluid, which is likely to contain less than a proportional amount of unwanted proteins.

20

#### **Pre-adsorption of Retroviral Vector Particles**

As noted above, the retroviral particles can be pre-adsorbed onto a surface that promotes adherence of the retroviral particles. Optimal transduction using RD114-pseudotyped vectors of stem cells can be obtained by preloading/adsorption of vectors on  
25 surfaces, *e.g.*, retronectin-coated culture dishes.

Suitable surfaces include, but are by no means limited to, plastic, glass, polymer particles (such as SEPHADEX and SEPHAROSE), gels, and the like. Preferred plastic surfaces are tissue culture vessels, flasks, or plates.

Preferably, the surface is coated with an adherence promoting agent. Such  
30 adherence promoting agents are typically biomolecules to which an RD114 pseudotyped virus adheres. Adherence can be detected by demonstrating the presence of more RD114 pseudotyped retroviral particles adhering to a surface in the presence relative to the

absence of an adherence promoting agent. In specific embodiments, the adherence promoting agent is retronectin, fibronectin, or polylysine; retronectin is exemplified *infra*.

To adsorb the retroviral particles, retroviral particle-containing supernatant from a producer cell culture is contacted with the solid surface for a time and under  
 5 conditions of temperature, pH, humidity, etc. that permit adsorption to occur. Once the particles are adsorbed, the supernatant can be decanted or otherwise removed. If desired, the adsorbed particles can be washed to remove additional impurities, *e.g.*, proteins from the supernatant, although the washing step should be done under mild conditions so as not to remove the pre-adsorbed retroviral particles.

10

### **Pre-adsorbed Transduction Kits**

Having shown that pre-adsorption of RD114 pseudotyped retroviral particles greatly increases transduction efficiency, it was further discovered that the pre-adsorbed particles could be stored for later use, thus permitting development of kits. Thus,  
 15 the invention encompasses a service for producing high efficiency retroviral vector particles.

A kit of the invention comprises retroviral vector particles pseudotyped with feline endogenous virus RD114 envelope protein and containing a gene of interest their genome pre-adsorbed onto a surface that promotes adherence of the retroviral  
 20 particles. As noted above, the retroviral vector particles are substantially free of producer cells and producer cell supernatant. Preferred kits employ plastic tissue culture containers (plates or vessels) as the surface to which the retroviral particles are adsorbed. The kits can be stored prior to use, preferably under conditions that preserve the transduction capability of the retrovirus particles, *e.g.*, about 50%, preferably greater than about 75%,  
 25 and more preferably greater than about 90% of the transduction potential of the retroviral particles at the time the kit is prepared. In a specific embodiment, the adsorbed particles are stored at -70°C. Experiments showed that the transduction efficiency was maintained after 48 hours of storage, one week of storage, and for longer periods under these conditions.

30

Accordingly, the invention provides a method for preparing such a kit. This method comprises contacting the surface with the retroviral vector particles for a sufficient period of time to permit adherence of the retroviral particles to the surface, and

removing supernatant in which the retroviral particles were suspended from the surface. The surface can be washed.

Thus, a vector production service can be implemented, in which a gene of interest is provided by a customer to the service lab, who introduce it into an RD114-  
 5 pseudotyped retroviral vector. The recombinant vectors are then adsorbed onto a suitable surface, *e.g.*, a retronectin-coated tissue culture dish, and provided to the customer. The customer can use this kit, containing retroviral vectors that express the customer's gene of interest, to transduce stem cells.

10

### **Transduced Animal Models**

Because of the high efficiency of transduction achieved by the present invention, it is possible to create animal models for human conditions by engrafting non-human animals with autologous or human stem cells transduced in accordance with the invention. Thus, the invention provides such non-human animals. Preferably, if the stem  
 15 cells are human stem cells the animal is immunodeficient, so that it does not reject the engrafted cells. However, in pre-clinical studies, engraftment with autologous cells is desired. The present inventors have successfully engrafted monkeys with the same high level of efficiency found with immunodeficient mice.

The animal models can be used to study the fate of marker-gene containing  
 20 transduced stem cells. Animal models in which the animals are engrafted with human stem cells can be used to study the effect of various pharmacological agents on the human cells, or to evaluate the effect of transgene production by the retroviral vectors on the animal physiology.

Suitable animals for these models include, but are by no means limited to,  
 25 mice, rats, rabbits, hamsters, guinea pigs, and other rodents; dogs, cats, and other domesticated carnivores; sheep, goats, pigs, and other farm animals; and monkeys, chimpanzees, apes, and other primates.

In specific embodiments, the invention discloses a NOD/SCID murine model and an immunodeficient simian model. In one specific embodiment, the present  
 30 invention discloses the use of RD114 pseudotyped oncoretroviral vector particles for transducing primitive human hematopoietic cells which are then injected into the bone marrow of NOD/SCID mice. According to this embodiment, the injected transduced stem

cells repopulated host bone marrow with around 90% efficiency leading to the introduction of a transgene into various hematopoietic cell lineages. In yet another embodiment, RD114 pseudotyped retroviral particles are used to transduce monkey hematopoietic stem cells, which were then injected into a recipient monkey. According to this embodiment, the attained efficiency of engraftment is around 70%.

### EXAMPLES

The invention may be better understood by reference to the following Examples, which is provided by way of exemplification and not limitation.

#### **EXAMPLE 1: Gene Transfer into Primitive Human Hematopoietic Cells Using Retroviral Vector Particles Pseudotyped with the Feline Endogenous Retrovirus (RD114) Envelope Protein**

##### Materials and Methods

**Cell lines and primary cell populations.** Human hematopoietic cell lines (K562-ATCC CCL 243 and HEL-ATCC TIB 180), mouse fibroblasts (NIH3T3-ATCC CRL 1658), and human embryonic kidney cells (293T-ATCC CRL 1573) were grown in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% Fetal Calf Serum (FCS). Human peripheral blood mononuclear cells (PBMC) were recovered from the blood of normal donors by centrifugation on Histopaque-1077 (Sigma). Human umbilical cord blood specimens were obtained from delivered placentas following uncomplicated births at a local delivery center. Mononuclear cell preparations were recovered by centrifugation on Histopaque-1077. The CD34<sup>+</sup> cells in the cord blood mononuclear cell specimens were purified using a CD34-specific magnetic cell selection system according to instructions provided by the manufacturer (Miltenyi Biotec, Bergisch Gladbach, Germany). CD34<sup>+</sup>, CD38<sup>-</sup> cells were recovered from the CD34<sup>+</sup> enriched populations by labeling with anti-CD34 (clone MY10) and anti-CD38 (clone HB-7) monoclonal antibodies (Becton Dickinson, San Jose, CA) conjugated to fluorescein isothiocyanate (FITC) or phycoerythrin (PE), respectively, and sorted for the CD34<sup>+</sup>, CD38<sup>-</sup> population using a vantage flow cytometer (Becton Dickinson).

**Retroviral vector preparations.** Vector particles pseudotyped with the feline endogenous virus (RD114) envelope protein were derived by generating producer

cells from a packaging cell line designated FLYRD18 (Porter *et al.*, Hum. Gene Ther., 1996, 7:913-919) Cossett, J. Virol., 1995, 69:7430; ECACC Accession No. 95091902. This packaging cell line had been derived from human sarcoma cells (HT1080) by introducing the *gag-pol* genes from murine leukemia virus (MuLV) and the *env* gene encoding the envelope protein of the RD114 virus. We derived producer cells from the FLYRD18 packaging cell line by introducing a vector genome (MGirL22Y) that encodes the enhanced green fluorescent protein (EGFP) and a drug resistant variant of human dihydrofolate reductase (L22Y) (Allay *et al.*, Nat. Med., 1998, 4:1136-1143; Persons *et al.*, Nat. Med., 1998, 4:1201-1205). The reading frames for these proteins are separated by an internal ribosomal entry site and transcribed into a bicistronic transcript under the control of the mouse stem cell virus (MSCV) long terminal repeat (LTR) (Cheng *et al.*, Gene Therapy, 1997, 4:1013-1022). The transduced FLYRD114 cells were selected in trimetrexate or sorted for high EGFP expression as previously described (Allay *et al.*, *supra*; Persons *et al.*, *supra*). Individual clones were recovered by limiting dilution and their capacity for vector production was determined by assaying serial dilutions of conditioned medium on human HeLa cells and a high titer clone designated RD114/MGirL22Y was identified. This methodology was also used to obtain amphotropic producer cell populations, AM13/MGirL22Y and AM/MGirL22Y, generated from FLYA13 packaging cells (a derivative of HT1080; Cosset *et al.*, 1995, J. Virol., 69:7430-7436) and PA317 packaging cells (Miller and Buttimore, 1986, Mol. Cell. Biol., 6:2895-2902) (ATCC Accession No. CRL 9078), respectively. GALV pseudotyped particles were generated by a producer clone derived from PG13 cells (Miller *et al.*, 1991, J. Virol., 65:2220-2224) (ATCC Accession No. CRL 10686), and VSV-G pseudotyped particles were generated by a producer clone derived from 293T cells (Ory *et al.*, 1996, Proc. Natl. Acad. Sci. USA, 93:11400-11406) using the techniques described above.

Vector preparations were screened for replication-competent virus by a marker rescue assay using HeLa (ATCC Accession No. CCL 2) or K562 (ATCC Accession No. ATCC CCL 243) cells which contained an integrated vector genome encoding neomycin resistance (G1NA).

Vector particles pseudotyped with the RD114, VSV-G, or amphotropic envelope proteins were also generated in 293T cells which had been transfected with helper and vector plasmids (Persons *et al.*, Blood Cells Mol. Dis., 1998, 24:167-182). For

RD114 pseudotyped particles, the 293T cells were transfected with a plasmid containing the vector genome (pMGirL22Y), a second plasmid encoding the gag and pol proteins of MuLV (pEQPAM3-E), and a third plasmid encoding the env protein of RD114 feline endogenous retrovirus (pRDF). Between 48-72 hours following transfection, conditioned media was harvested, titered on HeLa cells and screened for replication-competent retrovirus by the marker rescue assay as described above.

***In vitro analysis of gene transfer efficiency.*** All transductions were performed in medium which contained 6 mg/ml of polybrene. Various human and murine cell lines were transduced at specified multiplicities of infection (MOI) based on titers determined on HeLa cells. After an overnight incubation, the vector containing culture medium was removed and fresh medium was added. The cells were harvested 72 hours after transduction and analyzed for EGFP expression by flow cytometry (FACS caliber, Becton Dickinson, San Jose, CA).

Peripheral blood mononuclear cells (PBMC) (lymphocytes) were activated with phytohemagglutinin (PHA, 34mg/ml) and interleukin-2 (IL-2, R&D Systems) at 100U/ml for 48 hours in RPMI-1640 medium supplemented with 10% FCS for 48 hours prior to transduction. These activated human PBMC ( $2 \times 10^4$ /well) were then transduced in 48-well plates that had been coated with retronectin (CH-296, Takara Shuzo, Otsu, Japan) at a concentration of 20mg/cm<sup>2</sup>. Fresh medium containing IL-2 (100U/ml) was used to replace the vector containing medium after overnight incubation and the cells were allowed to expand for 72 hours post-transduction before analysis by flow cytometry. Analysis showed that more than 95% of the cells reacted with an anti-CD3 specific monoclonal antibody (data not shown).

CD34<sup>+</sup> or CD34<sup>+</sup>, CD38<sup>-</sup> purified primitive hematopoietic cell populations were cultured in Iscove's Modified Dulbecco's Medium (IMDM) plus 1% bovine serum albumin, human insulin (5mg/ml), human transferrin (100mg/ml), low density lipoproteins (10mg/ml), 0.1mM  $\beta$ -mercaptoethanol, stem cell factor (SCF, 300ng/ml), Flt-3 ligand (300ng/ml), interleukin-3 (IL-3, 10ng/ml) and interleukin-6 (IL-6, 10ng/ml). The cytokines were obtained from R&D Systems, Minneapolis, Minnesota. The cells were incubated for 24 hours at 37°C in 5% CO<sub>2</sub> prior to transduction.

Transduction of the CD34<sup>+</sup> and CD34<sup>+</sup>, CD38<sup>-</sup> cells was performed in retronectin coated 48-well plates ( $1-2 \times 10^4$  cells per well at a concentration of  $1-2 \times 10^5$

cells/ml). When indicated, the retronectin coated wells were pre-loaded with retroviral vector particles by placing 0.5ml/cm<sup>2</sup> of medium conditioned by producer cells in each well and incubating for 20-30 minutes at room temperature. This medium was then aspirated and a serum-free culture medium (specified above) containing CD34<sup>+</sup> or CD34<sup>+</sup>, CD38<sup>-</sup> purified cells was added. When transductions were performed without preloading, serum-containing medium (10% FCS) conditioned by producer cells was added to achieve the specified MOI in amounts up to 40% of the initial culture volume.

Gene transfer efficiency was analyzed by evaluating EGFP expression in transduced cells. After incubation, the CD34<sup>+</sup> or CD34<sup>+</sup>, CD38<sup>-</sup> cells were washed in PBS containing 2% heat-inactivated FCS and then stained with mouse anti-CD38 (clone HB-7) and anti-CD34 (clone My10) monoclonal antibodies conjugated to PE or allophycocyanin (APC, Becton Dickinson, San Jose, CA), respectively, washed, and resuspended in PBS containing 2% FCS. Four color flow cytometry was performed and the data were analyzed using the Cell Quest Software Package (Becton Dickinson).

To assay gene transfer into clonogenic progenitors, transduced and control hematopoietic cells were replated after 96 hours of culture into Methocult GF (H4434, Stem Cell Technologies, Vancouver, B.C., Canada) which had been pretreated with 1.2U/ml thymidine phosphorylase at 37°C for two hours. Cultures were established with or without 100nM trimetrexate. At this concentration of trimetrexate, no colonies were formed in the samples containing control (untransduced) cells. Hematopoietic cells were cultured in 35mm plates (1ml of medium per plate) at 37°C in a 5% CO<sub>2</sub> humidified atmosphere for 10-15 days after which the colonies were enumerated.

***Analysis of gene transfer into cells that establish human hematopoiesis in immunodeficient (NOD/SCID) mice.*** Purified CD34<sup>+</sup> cells were prestimulated in medium containing SCF, Flt-3 ligand, IL-3 and IL-6 as described above for 24 hours at a concentration of 1-2x10<sup>5</sup> cells/ml. The cells in this medium were then transferred to retronectin coated culture plates to which vector particles had been absorbed (pre-loaded) or to retronectin coated plates without virus. In the later case, vector particles were added in the form of conditioned medium (constituting up to 20% of the culture volume). All cultures were diluted 2-fold with serum-free medium containing cytokines at 48 hours and harvested for injection at 96 hours.



5 The NOD/SCID mice (Jackson Laboratories, Bar Harbor, Maine) were housed in sterile microisolator cages and supplied with sterile food, acidified water and bedding. These six- to eight-week-old mice were used after sublethal irradiation (3-5cGy-<sup>127</sup>Cs source). Each mouse was injected with  $1-1.5 \times 10^5$  freshly isolated CD34<sup>+</sup> cells (>95% purity) or after expansion of this input volume for up to 96 hours in culture. The mice were sacrificed 8-10 weeks following injection and bone marrow cells were harvested for flow cytometric analysis and *in vitro* culturing.

10 Bone marrow cells from animals injected with human cells was subjected to flow cytometric analysis using conjugated antibodies against human surface antigens as follows: 1) CD45-APC to screen human hematopoietic cells; 2) CD19-PE to screen B-lymphocytes; and 3) CD33-PE to screen myeloid cells. These antibodies were obtained from Pharmingen (San Diego, California). 5-10  $\times 10^5$  bone marrow cells were mixed with either rat anti-mouse CD16/CD32 Fc block (clone 2.4G2, Pharmingen) or 10% heat-inactivated pooled mouse serum (to block non-specific antibody binding), and then incubated with saturating amounts of one of the conjugated antibodies. Cells from each animal were also stained with appropriate conjugated, isotype matched, control antibodies obtained from Becton Dickinson or Pharmingen. After incubation, cells were resuspended in red cell lysis buffer and washed twice in PBS containing 2% FCS. In all experiments cells stained with the isotype control antibody were used to set the quadrant markers such that the negative quadrant contained at least 97% of the control cells. The percentage of engrafted human cells was determined by CD45 positivity, followed by the determination of lineage marker and EGFP expression in the CD45<sup>+</sup>-gated population.

25 The number of total and trimetrexate-resistant human clonogenic progenitors was determined in aliquots of bone marrow cells as described above. After 10-14 days, individual colonies were plucked from the methylcellulose and processed to recover DNA. Specifically, after scoring the plates, 20 colonies (or less, if fewer were present) were picked at random and incubated in lysis buffer [50 mM Tris (pH 8.5), 1 mM EDTA, 0.5% Tween 20, and 100 ug/ml proteinase K] at 56°C for 2 hours. To inactivate the proteinase K, the samples were heated at 95°C for 10 minutes. The DNA samples were assayed for EGFP coding sequences using the polymerase chain reaction (PCR) methodology. PCR was performed with PCR Core Kit (Boehringer Mannheim) according to the manufacturer's instructions. The amplification conditions were as follows: 92°C for

2 min., then 35 cycles of 92°C for 1 min., 60°C for 1 min., and 72°C for 1 min., followed by a final elongation step of 7 min. at 72°C. Primers which amplify a 829 base pair (bp) fragment of human alpha satellite DNA, 5'-AATTCAGCTGACTAAACA-3' (SEQ ID NO:4) and 5'-TTTAGTTAGGTGCAGTTAT-3' (SEQ ID NO:2), were used to confirm the presence of human DNA in each sample. The PCR amplification of the EGFP gene was performed with the primers 5'-ACCCCGACCACATGAAGCAGC-3' (SEQ ID NO:3) and 5'-CGTTGGGGTCTTTGCTCAGGG-3' (SEQ ID NO:4), resulting in a 417 bp product. Primers specific to the  $\beta$ -actin gene, 5'-TGACGGGGTCACCCACACTGTGCCCATCTA-3' (SEQ ID NO:5) and 5'-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3' (SEQ ID NO:6), were used as an internal control and gave a 604 bp product. The PCR products were electrophoresed on a 1% agarose gel with ethidium bromide staining to visualize DNA. Samples that failed to produce PCR fragments for either  $\beta$ -actin or alpha satellite DNA were not included in the calculation of gene transfer efficiency.

## Results

***Enhanced transduction of human hematopoietic stem cells with RD114 pseudotyped vector particles.*** The titer of infectious particles of various oncoviral vector preparations (*i.e.*, RD114, amphotropic, GALV, and VSV-G pseudotyped vector particles containing MGirL22Y retroviral genome) was determined prior to transduction by limiting dilution on HeLa cells. Human cord blood CD34<sup>+</sup> cells were cultured for 24 hours in cytokine-containing, serum-free medium (*see above*) and then transduced on retronectin coated plates. Serum-containing (10% FCS), conditioned medium from producer cells was added in amounts necessary to achieve the specified MOIs (but not exceeding 40% of the culture volume). After 24 hours fresh, serum-free cytokine-containing medium was added in amounts equal to the culture volume (2X dilution), and, after an additional 48 hours, the cells were analyzed for EGFP expression. With a single exposure at MOI of 5, the RD114 pseudotyped particles were far more efficient at transducing human CD34<sup>+</sup> cells than were vector particles pseudotyped with the amphotropic, GALV, or VSV-G env proteins. Human T-lymphocytes activated by PHA and IL-2 and human leukemia cells (K562 and HEL) were also far more efficiently transduced with RD114 than with amphotropic pseudotyped particles.

5 Aliquots of cells transduced with either RD114 or amphotropic  
pseudotyped particles were replated in methylcellulose immediately following  
transduction (48 hours of culture) and incubated for an additional 10-15 days, and the  
resistance to trimetrexate was determined. The RD114 pseudotyped vector efficiently  
transduced CD34<sup>+</sup> cells and their progenitors at a very low MOI indicating the presence of  
10 the appropriate receptor and cycling of a significant proportion of the cell population.  
Amphotropic pseudotyped particles failed to efficiently transduce the same population  
even at increased particle concentrations, consistent with a block to transduction at the  
receptor level.

*Medium conditioned by derivatives of the HT1080 cell line alters the  
immunophenotype of primitive human hematopoietic cells during transduction.* The  
immunophenotype of purified CD34<sup>+</sup> and CD34<sup>+</sup>, CD38<sup>-</sup> cells was routinely monitored  
following *in vitro* culture and transduction. After 96 hours in serum-free culture medium  
with high dose of cytokines, purified CD34<sup>+</sup>, CD38<sup>-</sup> cells retained their phenotype (*see*  
also Bhatia *et al.*, J. Exp. Med., 1997, 186:619-624). In contrast, the exposure of CD34<sup>+</sup>,  
CD38<sup>-</sup> cells to the medium conditioned by the RD114/MGirL22Y producer cells during  
transduction caused the majority of CD34<sup>+</sup>, CD38<sup>-</sup> cells to become CD38<sup>+</sup>. While only a  
small decrease in total clonogenic progenitors accompanied this phenotypic change (p-  
NS), the inventors have found that CD34<sup>+</sup> cells exposed to conditioned medium from the  
RD114/MGirL22Y producer cells failed to engraft in murine NOD/SCID recipients (N=4).  
25 In the same experiment, control CD34<sup>+</sup> cells (cultured identically but without exposure to  
vector particles) exhibited multilineage engraftment.

The observed phenotypic changes during transduction and the loss of  
primitive, repopulating cells may be caused directly by the RD114 env protein or,  
alternatively, may arise due to the action of some other component within the medium  
conditioned by the RD114/MGirL22Y producer cells. The later possibility seems more  
30 likely in light of finding that the culture medium from an amphotropic producer cell  
population (derived from the same original cell line, HT1080, as the producer cells for  
RD114 pseudotyped particles; Sommerfelt *et al.*, Virology, 1990, 176:58-69), induced a  
similar immunophenotypic change in CD34<sup>+</sup>, CD38<sup>-</sup> cells, *i.e.*, differentiation to a CD38<sup>+</sup>  
35 phenotype. In contrast, the culture medium from an amphotropic producer cell line of a  
different origin (*i.e.*, derived from PA317 cells) did not affect the immunophenotype of the

CD34<sup>+</sup>, CD38<sup>-</sup> cells. RD114 pseudotyped producer cells were also derived from 293T cells (*see above*). The culture medium from these cells had no effect on the immunophenotype of CD34<sup>+</sup>, CD38<sup>-</sup> cells indicating that the immunodifferentiating/eliminating substance is indeed HT1080 cell-specific.

***Transduction of primitive human hematopoietic cells by RD114***

***pseudotyped vector particles which had been pre-loaded onto retronectin coated plates.***

To provide the proper conditions for engraftment of transduced hematopoietic stem cells in murine NOD/SCID recipients the inventors set to prevent the undesirable effect of HT1080 cell-specific substance inducing the immunophenotypic change of CD34<sup>+</sup>, CD38<sup>-</sup> cells and the elimination of repopulating cells. Two alternative approaches were chosen.

According to the first approach, vector particles used for transduction were concentrated (and the volume of the culture medium containing harmful substances was greatly reduced) by ultracentrifugation at 25,000rpm for 90 minutes. Thus, in the experiment presented in the viral supernatant was concentrated 54-fold with highly efficient recovery of the particles (60%) without any loss of the transduction efficiency.

According to an alternative approach, retroviral vector particles were adsorbed or “pre-loaded” onto retronectin coated plates by a brief incubation with virus-conditioned medium (Williams, Ann. NY Acad. Sci., 1999, 872:109-113). In this way the vector particles become concentrated on the retronectin allowing the conditioned medium (containing a phenotype-altering substance) to be removed and replaced by medium containing the target cell population. Using conditioned medium from the RD114/MGirL22Y producer cells, the RD114 pseudotyped particles were adsorbed onto retronectin and then used to transduce CD34<sup>+</sup>, CD38<sup>-</sup> cells. This experimental approach proved to eliminate the undesirable effect of the HT1080-derived culture medium as it maintained the immunophenotype of the CD34<sup>+</sup>, CD38<sup>-</sup> cells with preservation of transduction efficiency. Transduction efficiency of pre-adsorbed viral particles remains unchanged after incubation for 48 hours at 4°C and upon long-term storage (greater than 1 week) at -70°C. Transduction efficiency of pre-adsorbed viral particles is cell concentration dependent with the optimal efficiency obtained at a concentration of 1-5 x 10<sup>4</sup> cells/cm<sup>2</sup>.

Further experiments using CD34<sup>+</sup>, CD38<sup>-</sup> cells were performed to determine the optimum period of prestimulation prior to the transfer of the target cell

population to retronectin coated plates pre-loaded with RD114 pseudotyped particles (N=4). Significant transduction of clonogenic progenitors (as reflected by trimetrexate resistance) was achieved already after 24 hours of prestimulation ( $38 \pm 15\%$ ;). However, the maximal effect was seen only after 48 hours of prestimulation ( $73 \pm 12\%$ ;).

***Transduction of human cells capable of establishing hematopoiesis in immunodeficient mice with RD114 pseudotyped vector particles.*** Purified CD34<sup>+</sup> cells which had been prestimulated for 24-48 hours in serum-free medium were transduced by a single exposure to RD114 vector particles pre-loaded onto retronectin coated plates. After a maximum of 96 hours of culturing, expanded cells derived from an input  $1.0-1.5 \times 10^5$  cells were injected into NOD/SCID immunodeficient murine recipients. Control cells were either not exposed to retroviral vector particles or transduced with amphotropic vector particles under various conditions. Bone marrow cells of three animals were analyzed 8-10 weeks after they had received CD34<sup>+</sup> cells transduced with RD114 pseudotyped vector particles. In each animal, there was a substantial population of bone marrow cells which reacted with a human CD45-specific monoclonal antibody. Among these CD45<sup>+</sup> cells, the EGFP-positive cells were found in both the human lymphoid (CD19<sup>+</sup>) and the human myeloid (CD33<sup>+</sup>) cell populations and in all three animals.

Overall rates of human engraftment in the NOD/SCID murine recipients and the levels of EGFP expression were determined. EGFP-positive cells were found in very significant numbers only in animals which received RD114 transduced CD34<sup>+</sup> cells. The observed decrease in engraftment efficiency of CD34<sup>+</sup> cells transduced by the RD114 pseudotyped vector after 24 hours of prestimulation (compared to untransduced CD34<sup>+</sup> cells [ $p < 0.05$ ]) was ameliorated by longer prestimulation (48 hours) which also resulted in improved EGFP expression. In correlation with reports of others (Glimm *et al.*, Blood, 1999, 94:2161-2168; Henneman *et al.*, Exp. Hematol., 1999, 27:817-825), a 48 hour-long prestimulation of producer cells prior to transduction appears to be an optimal condition for maximal gene transfer into NOD/SCID repopulating cells. The efficiency of gene transfer into repopulating hematopoietic cells was also evaluated by PCR analysis of DNA recovered from expanded bone marrow cells of experimental animals. A high percentage of cell clones from animals that had received cells transduced with RD114 pseudotyped vector particles produced EGFP-specific PCR product (Table 1). Of interest is the fact

- 5 that the transduction frequencies of secondary progenitors of the CD34<sup>+</sup> cell population (Table 1) were comparable to those observed with primary progenitors.

Table 1

**Repopulation of NOD/SCID Mice by Transduced Cord Blood CD34<sup>+</sup> Cells:  
Analysis of Engraftment and Gene Transfer Efficiency**

Experimental Group	In Vitro Analysis		In Vivo Analysis			
	% EGFP Expression	% TMTX-R Progenitors	% Human CD45 <sup>+</sup> (range)	% EGFP <sup>+</sup> (range) <sup>0</sup>	Human Progenitors	
					Trimetrexate Resistant (%)	PCR+ Colonies (%)
<b>Expanded CD34<sup>+</sup> Cells (N=10)<sup>+</sup></b>	<b>0</b>	<b>0</b>	<b>13.5±17%</b> (2.18-54.5%)	<b>0%</b>	<b>0/228</b> (0%)	<b>0/20</b> (0%)
<b>AM/MGirL 22Y Transduced CD34<sup>+</sup> Cells (N=9)*</b>	<b>18-34%</b>	<b>6.5-8%</b>	<b>15.6±16%</b> (1.0-53%)	<b>0.2±0.1%</b> (0-0.6%)	<b>0/118</b> (0%)	<b>0/50</b> (0%)
<b>RD/MGirL2 2Y Preload Only @ 24 Hours (N=9)</b>	<b>75-87%</b>	<b>58-75%</b>	<b>3.5±5%<sup>a</sup></b> (0.6-15.8%)	<b>20.0±22%<sup>b</sup></b> (0.6-71%)	<b>24/106</b> (23%)	<b>30/61</b> (49%)
<b>RD/MGirL2 2Y Preload Only @ 48 Hours (N=6)</b>	<b>50-69%</b>	<b>45-66%</b>	<b>8.7±8%</b> (1.7-23.5%)	<b>40.5±40%<sup>b</sup></b> (1.8-92%)	<b>81/326</b> (25%)	<b>58/98</b> (59%)

<sup>a</sup> p<0.05 compared to controls recipients

<sup>b</sup> p<0.05 compared to AM/MGirL22Y

<sup>0</sup> Percent EGFP Expression of Engrafted Human Mononuclear Cells

<sup>+</sup> N = Number of murine recipients of 1.0-1.5 x 10<sup>5</sup> cells that exhibited > 0.5% human CD45<sup>+</sup> cells

\* Transduction by preloading alone @ 24 hours (N=3) or with the addition of conditioned medium containing vector particles added at 48, and 72 hours

### Discussion

The results presented above demonstrate that murine oncoretroviral vector particles pseudotyped with the envelope protein of feline endogenous virus (RD114) are

5 transduced into human primitive hematopoietic cell lines, the CD34<sup>+</sup> and CD34<sup>+</sup>, CD38<sup>-</sup> cell populations from cord blood, and the progenitors found in these populations far more efficiently than tested amphotropic, GALV and VSV-G pseudotyped oncoviral particles used at equivalent multiplicities of infection.

10 The disclosed producer cells generating the RD114 pseudotyped vector particles were derived from human sarcoma cells (HT1080) which apparently generate a substance that induces immunodifferentiation and depletion of repopulating cells. The nature and identity of this substance(s) is unknown and represents an important subject for future investigation. The evidence presented herein indicates that the RD114 pseudotyped particles are not the source of the substance since the same immunodifferentiation effect  
15 was observed with amphotropic particles produced by a derivative of the HT1080 cell line and was not observed with RD114 particles produced by human 293T cells.

20 As disclosed herein, the undesired effects of this substance could largely be avoided by preloading the RD114 particles onto retronectin plates prior to transduction of hematopoietic cell populations (although some depletion of NOD/SCID cells was observed compared to controls (Table 1). The ultimate solution may therefore involve the derivation of a RD114 packaging cell line from another cell type, such as NIH 3T3 mouse fibroblast cells which are currently the main source of vector preparations used in clinical trials.

25 As described above, cells in the cord blood CD34<sup>+</sup> population transduced with retronectin-adsorbed RD114 pseudotyped vector particles are capable of establishing human hematopoiesis in immunodeficient (NOD/SCID) mice as reflected by the presence of the proviral genome in as many as 90% of the myeloid and lymphoid cells in the bone marrow of the transplant recipients. These results are far superior to gene transfer obtained to date with any onco- or lentiviral system.

30 The frequency of genetically modified, secondary progenitors present in bone marrow 8-10 weeks following transplantation was approximately equivalent to the frequency of genetically modified primary progenitors in the transduced population used for transplantation of the immunodeficient mice. These results imply that the frequency of transduction of NOD/SCID repopulating cells was equal to the transduction frequency of  
35 progenitors which, in turn, was equivalent to the transduction of the entire CD34<sup>+</sup> cell population. In this respect, the results obtained in transducing human cord blood cells



5 with RD114 pseudotyped vector particles are comparable to those generally obtained in  
transducing murine hematopoietic cells with ecotropic vector particles (Allay *et al.*, *supra*;  
Persons *et al.*, *supra*). These results contrast with the general experience with amphotropic  
and GALV pseudotyped oncoretroviral vector particles in which the transduction  
10 frequency of more mature human CD34<sup>+</sup> cells and progenitors exceeds that of repopulating  
cells (van Henn, *et al.*, Blood, 1998, 92:4013-4022; Marandin *et al.*, 1998, Hum. Gene  
Ther., 9:1497-1511; Schlitz *et al.*, Blood, 1998, 92:3163-3171; Conneally *et al.*, Blood,  
1998, 91:3487-3493). Moreover, a higher frequency of transduction of human NOD/SCID  
15 repopulating cells was achieved with a single exposure to RD114 pseudotyped vector  
particles at a low MOI than with multiple exposures to amphotropic, GALV and VSV-G  
pseudotyped vector particles used at generally higher MOIs (*see also* van Henn, *et al.*,  
*supra*; Conneally *et al.*, *supra*; van Henn, *et al.*, *supra*; Marandin *et al.*, *supra*; Schlitz *et al.*,  
*supra*; Henneman *et al.*, *supra*; Rebel *et al.*, Blood, 1999, 93:2217-2224; Evans *et al.*,  
Hum. Gene Ther., 1999, 10:1479-1489). It can be therefore hypothesized that the neutral  
amino acid transporter which is used as a receptor for both RD114 and ecotropic  
20 pseudotyped particles (Albritton *et al.*, J. Virol., 1993, 67:2091-2096; Rasko *et al.*, Proc.  
Natl. Acad. Sci. USA, 1999, 96:2129-2134) is expressed at functionally higher levels on  
human primitive hematopoietic cells than is the phosphate transporter which serves as a  
receptor for amphotropic and GALV pseudotyped vector particles.

It has been reported that VSV-G pseudotyped lentiviral vector particles are superior  
25 to VSV-G pseudotyped oncoretroviral vector particles at transducing quiescent  
NOD/SCID repopulating cells (Miyoshi *et al.*, Science, 1999, 283:682-686). As discussed  
above, VSV-G pseudotyped oncoretroviral vector particles transduce NOD/SCID  
repopulating cells relatively inefficiently (Rebel *et al.*, *supra*) compared to the results  
obtained herein with RD114 pseudotyped vector particles. It can be inferred therefore that  
30 RD114 pseudotyped lentiviral vector particles may be even more superior than RD114  
pseudotyped oncoviral vector particles at transducing primitive hematopoietic cells.  
Recent results from the inventors' laboratory suggest that the RD114 pseudotyped  
lentiviral vector particles can be generated.

Taken together, the disclosed data suggest that (i) increasing the transduction and  
35 repopulation frequency by pretreating the target cells with cytokines and by immobilizing  
the retroviral vector particles on retronectin plates, (ii) overcoming the limitation imposed

by receptor density for vector particle entry with the RD114-specific envelope protein, and (iii) the use of lentiviral vector internal proteins to facilitate translocation of the preintegration complex through the nuclear membrane may result in highly consistent and efficient transduction and repopulation of human hematopoietic stem cells thereby making gene therapy applications highly feasible and predictably successful.

**EXAMPLE 2: Optimal Transduction Using RD114-Pseudotyped Vectors of Hematopoietic Stem Cells Requires Preloading/Adsorption of Vectors on Retronectin Coated Dishes and is Cell Concentration Dependent**

As disclosed in Example 1 (*supra*), use of the RD114-pseudotyped retroviral vector particles pre-adsorbed (pre-loaded) onto retronectin-coated plates improves efficiency of stem cell transduction and NOD/SCID mice engraftment. It is further disclosed in Example 1 that the use of retronectin coated plates can eliminate the effects of unidentified producer cell-derived factors on the target stem cell differentiation and survival during engraftment.

In light of the above, it is important to attain the maximal efficiency of transduction when using retronectin-coated plates. We hypothesized that the transduction efficiency of the retronectin-adsorbed particles will be dependent on their density on the plate. Indeed, we found that gene transfer efficiency was maximized using retronectin concentration greater than  $12 \mu\text{g}/\text{cm}^2$ . We further hypothesized that the transduction efficiency of the retronectin-adsorbed particles will be dependent on cell contact and, therefore, on cell concentration. Indeed, CD34<sup>+</sup> cells from cord blood (CB) were efficiently transduced by adsorbed RD114-pseudotyped murine retroviruses on retronectin coated dishes at a concentration of  $1-5 \times 10^4$  cells per  $\text{cm}^2$ . Data were obtained from representative experiments of 2 cords. It has been repeated twice with peripheral blood CD34<sup>+</sup> cells with similar results.

**EXAMPLE 3: RD114-Pseudotyped Murine Retroviruses Adsorbed to Retronectin Coated Plates Maintain Transduction Efficiency of Hematopoietic Stem Cells After Long-Term Storage at  $-70^\circ\text{C}$ /Dry Ice**

We evaluated the stability of RD114-pseudotyped retroviral particles. We found that retroviruses pseudotyped with the RD114 envelope protein have a longer half-life in solution as compared to amphotropic pseudotyped retroviruses. We hypothesized that this stability would also be seen in the vector particles pre-loaded to the retronectin coated plates. We used frozen aliquots of a high titered RD114-MGirL22Y supernatant for these experiment. Peripheral blood CD34<sup>+</sup> cells were transduced on 6 well plates prepared as follows: (i) pre-loaded and then frozen at 70°C for 48 hours before thawing, (ii) pre-loaded and placed at 4°C for 48hours, (iii) pre-loaded and placed at 4°C for 24 hours, or (iv) freshly pre-loaded with thawed supernatant. There was gradual loss of gene transfer efficiency using pre-loaded plates placed at 4°C as compared to pre-loaded plates prepared fresh. However, significant gene transfer efficiency could be maintained using pre-loaded plates that were kept frozen. We have subsequently repeated these experiments twice using plates stored at -70°C for greater than one week with similar results.

**EXAMPLE 4: RD114-Pseudotyped Murine Retroviruses Can be Concentrated by Ultracentrifugation with Preservation of Transduction Efficiency**

As disclosed in Example 1, to ensure the efficient retroviral-mediated gene transfer to stem cells, it is highly important to eliminate the effect of producer cell-derived factors on the target cell differentiation and survival during engraftment. Therefore, in parallel to developing the transduction protocols using viral particles pre-adsorbed on retronectin-coated plates (see Examples 1-3, *supra*), we separated the retroviral vector particles from the detrimental content of the producer cell culture media using ultracentrifugation.

The results show that RD114-pseudotyped vector particles can be collected in a concentrated form by ultracentrifugation at 25,000 rpm for 90 minutes at 4°C. In this experiment, the viral supernatant was concentrated 54-fold with 60% recovery of total particles.

The concentrated RD114 supernatant demonstrated greatly increased transduction efficiency when tested on HeLa cells. AZT was added to cells as a control to rule out pseudo-transduction. To determine the transduction efficiency, double color Facs

analysis was performed using peripheral blood transduced at 48 hours with GFP-pre-loaded virus, GFP-pre-loaded virus plus concentrated yellow fluorescent protein (YFP) plus supernatant at 48 hours, GFP-pre-loaded virus at 48 hours plus concentrated YFP plus supernatant at 72 hours, and GFP-pre-loaded virus at 72 hours.

5

**EXAMPLE 5: RD114 Envelope Protein Pseudotyped Lentiviral Constructs Can Be Concentrated by Ultracentrifugation**

As discussed in Example 1 (*supra*), the development of lentiviral-based retroviral vector particles can greatly improve the efficiency of gene transfer to the non-dividing cells. We have therefore set to obtain RD114-pseudotyped lentiviral vector particles which can be used for transduction of various quiescent stem cells.

We have first prepared lentiviral vectors transiently using VSV-G pseudotyping and have observed, as have others (*e.g.*, see Evans, *et al.*, Hum. Gene Ther., 1999, 10:1479-1489), that these vectors can efficiently transduce CD34<sup>+</sup>,CD38<sup>-</sup> cells while oncoretroviral particles pseudotyped with VSV-G do not.

We then sought to determine whether the RD114 envelope can pseudotype lentiviruses. We used two different transient transfection protocols and simultaneously derived VSV-G pseudotyped lentiviral vectors as an internal control to show that the transfection protocols worked. Supernatants from producer cells were collected and viral titers were determined using HeLa cells. We found that we could indeed pseudotype lentiviruses with the RD114 envelope protein.

While in the first series of experiments the titer of the RD114 pseudotyped lentiviral preparation was low, viral transduction did occur. We have determined that the low titer was the result of the poor expression of the envelope protein in the chosen producer system. In light of this observation, we have subsequently derived RD114-pseudotyped lentiviral particles with a much higher titer using a stronger promoter to drive the expression of RD114 envelope protein.

In addition, we have demonstrated that the RD114-pseudotyped lentiviral vector particles can be concentrated (as described in Examples 1-4, *supra*) by pre-loading on retronectin-coated plates or by ultracentrifugation.

**EXAMPLE 6: Repopulation of Hematopoietic Lineages of Immunodeficient Rhesus Monkey by Cord Blood CD34<sup>+</sup> Cells Transduced with RD114-pseudotyped Retroviral Vector Particles Pre-adsorbed on Retronectin-coated Plates**

5

**Materials and Methods**

G-CSF/SCF mobilized rhesus monkey peripheral blood CD34<sup>+</sup> cells were selected and purified as described by Donahue *et al.* (Blood, 2000, 95:445-452). These cells were pre-stimulated under serum-free conditions essentially as described in Example 1 for  
10 NOD/SCID-repopulating cells (*supra*), except that the cytokines were SCF (300ng/ml), Flt-3 ligand (300 ng/ml), and interleukin-6 (50ng/ml). Following 48 hour pre-stimulation, cells were placed on retronectin-coated plates pre-loaded with RD-114-pseudotyped retroviral vector particles (RD114-MGirL22Y; prepared and pre-loaded as described in Examples 1 and 2, respectively) along with fresh media and cytokines. Upon overnight incubation (72 hours  
15 total), cells were removed from the plates, pelleted by centrifugation, and resuspended again in fresh media supplemented with cytokines. Cell suspension was plated for the second time on fresh retronectin-coated plates pre-loaded with retroviral vector particles. Cells were harvested at 96 hours, washed with fresh media, and injected into immunodeficient rhesus monkeys.

20

**Results**

The efficiency of engraftment of CD34<sup>+</sup> cells transduced with RD114 pseudotyped vector particles in the hematopoietic lineages of the recipient monkey (96E113) was analyzed 0-106 days post-injection by monitoring EGFP expression. The percentage of  
25 hematopoietic cells expressing EGFP reached the maximal levels 64 days after injection, with the highest frequency of engraftment observed in monocytes (up to 98%) and peripheral mononuclear lymphocytes (PMN) (up to 83%). Lymphocytes and platelets also showed increased levels of EGFP expression, although not at the same level as monocytes or PMNs. Also, platelets achieved maximal EGFP expression at day 78 post transplantation.

30

\* \* \*

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described  
5 herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

It is further to be understood that all values are approximate, and are provided for description.

All patents, applications, publications, test methods, literature, and other  
10 materials cited herein are hereby incorporated by reference.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206